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ABSTRACT Preliminary research suggests that naloxone (Narcan), a short-acting opiate
antagonist, could be provided by prescription or distribution to heroin users to reduce
the likelihood of fatality from overdose. We conducted a random postal survey of
1,100 prescription-authorized health care providers in New York City to determine
willingness to prescribe naloxone to patients at risk of an opiate overdose. Among
363 nurse practitioners, physicians, and physician assistants responding, 33.4% would
consider prescribing naloxone, and 29.4% were unsure. This preliminary study sug-
gests that a substantial number of New York City health care providers would pre-
scribe naloxone for opiate overdose prevention.
INTRODUCTION
Preliminary research suggests that naloxone (Narcan) could be provided by prescrip-
tion or distribution to heroin users to reduce the likelihood of fatality from over-
dose.1 Naloxone is a potent and specific opioid receptor antagonist used clinically
to reverse an opiate overdose or the effects of opiate analgesia. Effects occur within
1–2 minutes of administration and last 45 to 90 minutes.2 Opiate overdose reversal
with naloxone is nearly universal, and adverse effects are rare at therapeutic doses.3,4
Naloxone is regulated as a prescription drug in the United States, but is neither
carried by nonhospital pharmacies nor traditionally prescribed for take-home use.
Naloxone was prescribed in conjunction with rescue breathing training in a trial in
2001–2002 in San Francisco, California5; since 1999 in Chicago, Ilinois6; and as
part of a state overdose prevention initiative in New Mexico since 2001. Since the
1980s, naloxone has been available as an over-the-counter medication in Italy7 and
distributed through low-threshold services in Berlin, Germany, and Jersey, United
Kingdom.8 Preliminary results from Berlin, Jersey,8 and Chicago6 document lifesav-
ing events through peer administration of naloxone and no observed adverse ef-
fects. Evaluations of the acceptability of naloxone distribution to drug users found
the proposal to be appealing and feasible.9–11
A survey of health care providers’ opinions about naloxone administration had
not been conducted. To explore the feasibility of a naloxone program in New York
City, we evaluated the willingness of providers to prescribe naloxone for patients
at risk of opiate overdose.
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METHODS
Through a Freedom of Information Act request, we obtained a list of all health
care providers with prescription authority (nurse practitioners [NPs], physicians
[MDs], and physician assistants [PAs]) registered with the New York Department
of Education. We limited NPs and MDs to a broad subset of medicine specialties
that address issues related to patients’ illicit drug use and drew a random sample
of 1,100 subjects. The sample was weighted to capture 70% MDs. A survey 7–10
minutes long was used that measured health care attitudes and practices surround-
ing several aspects of health care for injection drug users (IDUs). The New York
Academy of Medicine Institutional Review Board approved this study in April
2001.
RESULTS
There were 29 surveys that were undeliverable, and 364 providers responded within
6 weeks, for an overall response rate of 34.0%. A total of 363 responses were in-
cluded in the analysis. Males comprised 54.0%; 68.4% were white, 13.6% were
Asian or Pacific Islander, 9.4% were African American or black, and 5.8% were
Latino. In accordance with our weighted sample, 15.6% of respondents were NPs,
68.0% were MDs, and 16.4% were PAs. The largest plurality of respondents spe-
cialized in internal medicine (23.3%), psychiatry (17.5%), pediatrics (12.3%), and
general practice (10.4%). Over one third (39.6%) practiced in an office, 32.1% in
a hospital, 14.8% in a clinic, and 2.5% in other settings. One fifth (19.8%) directed
a program or clinic. Most respondents had panels of 40–600 patients. Nearly one
quarter (24.7%) reported active IDUs in their panel, and among those respondents,
45.7% reported that more than 5% of their panel were IDUs.
Overall, 33.4% of respondents reported that they would consider prescribing
naloxone to patients at risk of opiate overdose; 29.4% were unsure, and 37.1% would
not prescribe naloxone (see Table). There were no significant differences in support
by provider characteristics. Among respondents with active IDUs in their panel,
46% would consider prescribing naloxone, although this difference was not signifi-
cant. Specialties for which at least 40% would prescribe naloxone included family
practice (45%), gynecology (50%), critical care (42%), and addiction psychiatry
(40%).
TABLE. Percentage that would consider prescribing naloxone
to patients at risk of heroin overdose
Yes, % Unsure, % No, %
Total 33 29 37
Nurse practitioner (N = 57) 30 44 26
Physician (N = 234) 33 26 41
Physician assistant (N = 59) 37 31 32
Active IDUs in panel (N = 69) 46 22 32
No active IDUs in panel (N = 210) 33 27 40
IDU, injecting drug user.
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DISCUSSION
The response rate is low for epidemiologic research, but is within the normal range
for postal surveys and relatively high for postal surveys of this population. We did
not study the reasons respondents would or would not prescribe naloxone. Con-
cerns about prescription have been addressed in other studies. Burris et al.12 found
no likely legal risks to providers from prescription of naloxone in the United States.
Surveys of drug users found that naloxone distribution is unlikely to lead to more
opiate use, if only due to the unpleasant effects of naloxone.10 Among 34 peer
naloxone administrations, Dettmer et al.8 found administration to be inappropriate
in only 1 case (a cocaine overdose). Premature reinjection of heroin leading to a
new overdose has not been found to be a problem among overdose patients released
against medical advice after naloxone administration.13 Nonetheless, these and
other risks should be addressed and monitored in any distribution program.
These preliminary data suggest that a substantial portion of health care providers
in New York City would prescribe naloxone for opiate overdose prevention. Support
may be greater for more comprehensive naloxone programs, including training in
the administration of naloxone, rescue breathing, or cardiopulmonary resuscitation.
Further research should identify concerns about naloxone prescription and evaluate
provider and patient experiences in naloxone distribution initiatives.
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